Repligen Announces Agreement to Acquire ARTeSYN Biosolutions
ARTESYN
BioSolutions
Meets
Repligen's
Acquisition
Criteria
R REPLIGEN
4
Technology leadership in bioprocessing
A gold standard in Single-Use Systems design and performance, highly differentiated
✓ Strengthens and expands Repligen portfolio
●
●
Addresses gap in Filtration with TFF Flat Sheet System
Expands Systems portfolio
Filtration, Chromatography, Media/Buffer Prep, Custom Continuous Manufacturing
Supply chain control
Integrates EMT and ProConnex flow paths in Systems portfolio
Operational and commercial leverage
●
ARTESYN has minimal salesforce today - leverage Repligen's commercial team
Strong operational synergies in Systems and Flow Path assemblies
Growing revenues, improving margins as ARTESYN business expands
2021 focus on building commercial and expanding pipeline opportunities
Leveraging EMT - expands margins and secures the supply chain for key components
Expected to be breakeven to adjusted EPS in 2021 and accretive in 2022
~$200M purchase (~$130M cash, $70M shares), 6x-7x 2020e Revenue
ARTeSYN
BiosolutionsView entire presentation